Clinical trials: Fibrosis and Cirrhosis of Liver
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
AGED Diagnostics Clinical Validation Study
Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate two investigational blood tests developed by AGED Diagnostics for the…
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Trial name
- NCT07867574
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Blood Collection Biorepository for Liver Disease Research
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the…
- Conditions
- Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
- Trial name
- NCT03025074
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Liver Fibroses, Cirrhosis
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
- Trial name
- TORCH (NCT05028829)
- Testing
- Atorvastatin 20mg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Raymond Chung
Cirrhosis, End Stage Liver DIsease
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
- Conditions
- Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
- Trial name
- NCT05205954
- Testing
- Hepatology Home Hospital
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Liver Fibrosis
The Phase Ⅰd Clinical Trial of Hydronidone Capsules
Based on the Phase I (Ia, Ib, Ic) clinical pharmacokinetic study of Hydronidone Capsules, a clinical pharmacokinetic trial of Hydronidone Capsules (specification: 30 mg/capsule) was conducted, including single-dose…
- Trial name
- NCT07262346
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
Liver Fibrosis, Cirrhosis
Endosonographic Shear Wave Elastography to Assess Liver and Splenic Fibrosis
The study is being done to collect information on the effectiveness of endosonographic elastography (a technique which uses sound waves) to measure the stiffness of the liver and spleen.
- Trial name
- EUS SWE liver (NCT06867731)
- Testing
- Endosonographic Elastography, Endosonographic shear wave elastography
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Providence Medical Research Center
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Hepatic Impairment, Cirrhosis
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
- Conditions
- Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
- Trial name
- NCT05045482
- Testing
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Cirrhosis, Liver Failure
Empagliflozin in Patients With Cirrhosis and Ascites
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites.
- Trial name
- EMPA Liver (NCT05726032)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Portal Hypertension, Chronic Liver Disease (CLD)
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG
The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative…
- Conditions
- Portal Hypertension, Chronic Liver Disease (CLD), Cirrhosis
- Trial name
- EUS-PPG (NCT06863012)
- Testing
- Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement, Hepatic Venous Pressure Gradient (HVPG) Measurement
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
Lipid Profiles, Cirrhosis, Liver
Effect of LSD on Lipid Profiles Within 1 Year Postoperatively in Cirrhosis Patients With Portal Hypertension Bleeding
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension.
- Conditions
- Lipid Profiles, Cirrhosis, Liver, Portal Hypertension, Splenectomy; Status
- Trial name
- LSD-LPPH (NCT07811700)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension
Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites).
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Renal Function Abnormal, Portal Hypertension
- Trial name
- NCT07811713
- Testing
- Laparoscopic splenectomy and azygoportal disconnection
- Volunteers
- 496 people
- Sponsor
- Northern Jiangsu People's Hospital
Hepatic Impairment, Cirrhosis
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of…
- Trial name
- NCT05484206
- Testing
- VIR-2218, VIR-3434
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Biliary Atresia, Kasai Operation
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia
Biliary atresia is a progressive liver disease in infants where liver transplantation is often the only long-term option once cirrhosis develops.
- Conditions
- Biliary Atresia, Kasai Operation, Liver Fibrosis, Stem Cell
- Trial name
- NCT07797673
- Testing
- Umbilical Cord-Mesenchymal Stem Cells (UC-MSC), Kasai Portoenterostomy
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Cirrhosis, Ascites Hepatic
Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Disease
The goal of this observational study is to see if repeated bedside ultrasound measurements of the lungs and abdomen as well as a blood vessel in the neck can be done in patients with advanced liver disease and ascites (fluid in…
- Conditions
- Cirrhosis, Ascites Hepatic, Fluid Balance
- Trial name
- POCUS-C (NCT07810855)
- Testing
- Ultrasound measurement, Blood draw for the laboratory assessment
- Volunteers
- 100 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust